In today’s session Allergan plc Ordinary Shares (AGN) recorded an unusually high (1,167) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious AGN decrease. With 1,167 contracts traded and 1214 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: AGN161216P00180000 closed last at: $6.1 or 183.7% up. About 2.38 million shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 17.56% since April 5, 2016 and is downtrending. It has underperformed by 19.52% the S&P500.
Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage
Out of 18 analysts covering Allergan Inc. (NYSE:AGN), 14 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 78% are positive. $400 is the highest target while $232 is the lowest. The $297.80 average target is 50.15% above today’s ($198.34) stock price. Allergan Inc. has been the topic of 45 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Thursday, November 3 by RBC Capital Markets. The firm has “Buy” rating by Mizuho given on Friday, October 9. The firm earned “Neutral” rating on Thursday, April 7 by Susquehanna. Guggenheim initiated Allergan plc Ordinary Shares (NYSE:AGN) on Monday, April 18 with “Neutral” rating. The stock of Allergan plc Ordinary Shares (NYSE:AGN) earned “Buy” rating by Goldman Sachs on Monday, April 18. The firm earned “Buy” rating on Friday, August 7 by Deutsche Bank. Mizuho maintained the stock with “Buy” rating in Friday, November 13 report. The firm earned “Buy” rating on Tuesday, September 29 by Nomura. Mizuho maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Tuesday, October 11. Mizuho has “Buy” rating and $299 price target. As per Friday, February 19, the company rating was initiated by Wells Fargo.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 0.46 in Q2 2016. Its down 0.29, from 0.75 in 2016Q1. The ratio fall, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Connors Investor Services Inc accumulated 0.04% or 1,000 shares. Amer Rech & Mgmt Com last reported 0% of its portfolio in the stock. Mitchell Mcleod Pugh Williams owns 3,975 shares or 0.83% of their US portfolio. Frontier Mgmt accumulated 32,758 shares or 0.94% of the stock. Gemmer Asset Management Ltd Liability Corporation has invested 0.02% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN). Mengis Mgmt Inc holds 1.27% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 6,210 shares. Bartlett & Com Limited Liability Company reported 494 shares or 0.01% of all its holdings. The California-based Grassi Inv Management has invested 0.22% in Allergan plc Ordinary Shares (NYSE:AGN). Armstrong Henry H Assoc Incorporated last reported 3,690 shares in the company. Chartist Ca holds 0% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 1,844 shares. Dowling Yahnke Limited Liability Corp accumulated 0.06% or 2,145 shares. Marshwinds Advisory holds 0.1% or 927 shares in its portfolio.
AGN Company Profile
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States. The Firm has global rights to RST-001, a gene therapy approach for the potential treatment of retinitis pigmentosa (RP). The RST-001 optogenetic approach includes a photosensitivity gene, channelrhodopsin-2, to create new photosensors in retinal ganglion cells to restore vision in retinal degenerative conditions. The RST-001 is in Phase I/IIa clinical trials. It has global rights to AKN-083, a preclinical farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH).
More recent Allergan plc Ordinary Shares (NYSE:AGN) news were published by: Investorplace.com which released: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. Also Investorplace.com published the news titled: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s news article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” with publication date: April 05, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.